Unidad de Hepatología, Servicio de Aparato Digestivo, Institut de Recerca Germans Trias i Pujol (IGTP), Hospital Germans Trias i Pujol, Badalona, Barcelona, España; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Badalona, Barcelona, España; Childhood Liver Oncology group (c-LOG), Program of Predictive and Personalized Medicine of Cancer (PMPPC), Institut de Recerca Germans Trias i Pujol (IGTP), Badalona, Barcelona, España.
Unidad de Hepatología, Servicio de Aparato Digestivo, Institut de Recerca Germans Trias i Pujol (IGTP), Hospital Germans Trias i Pujol, Badalona, Barcelona, España; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Badalona, Barcelona, España; Innate Immunity Group, Germans Trias i Pujol Health Sciences Institute (IGTP), Badalona, Barcelona, España.
Med Clin (Barc). 2018 May 23;150(10):390-397. doi: 10.1016/j.medcli.2017.08.010. Epub 2017 Oct 31.
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide with over 740,000 new cases per year and the third leading cause of cancer-related death, with a growing incidence in recent years. This tumor usually arises in patients with an underlying chronic liver disease. The management of this tumor has improved over the past 2 decades: patients at risk are included in a surveillance program, a prognostic staging system has been created and, finally, new treatments particularly aimed at patients with advanced HCC have been developed. This fact has resulted in a greater interest in this tumor and several scientific societies have developed clinical practice guidelines for the management of patients with this disease. In this article, we review the current and future prospects of this tumor.
肝细胞癌 (HCC) 是全球第六大常见癌症,每年新增病例超过 74 万例,是癌症相关死亡的第三大原因,近年来发病率呈上升趋势。这种肿瘤通常发生在患有潜在慢性肝病的患者中。在过去的 20 年中,这种肿瘤的治疗已经得到了改善:处于危险中的患者被纳入监测计划,创建了预后分期系统,最后,还开发了专门针对晚期 HCC 患者的新治疗方法。这一事实使得人们对这种肿瘤产生了更大的兴趣,几个科学协会已经为这种疾病患者的管理制定了临床实践指南。在本文中,我们回顾了这种肿瘤的现状和未来前景。